Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and infection anxiety on adherence and ability to self-inject

The management of many chronic illnesses involves medications that must be injected on a frequent basis. With fewer support resources available, patients are increasingly being obliged to manage injectable medications themselves. Interferon beta-1a (IFNβ-1a), recommended for the treatment of multiple sclerosis (MS), must be injected intramuscularly on a weekly basis. Patients are generally advised and taught to self-inject, if possible. This longitudinal study examined cognitive and affective contributions to the ability to self-inject and adherence to IFNβ-1a over 6 months following initiation of medication. Participants were 101 patients with a relapsing form of MS. Injection self-efficacy expectations, injection anxiety, adherence expectations, method of injection administration, and 6-month adherence to IFNβ-1a were fitted to a path analytic model Pretreatment injection self-efficacy expectations were significantly related to 6-month adherence. This relation was mediated by the patient's ability to self-inject. Patients’experienced level of injection anxiety was related to adherence but not to method of injection.

[1]  K. Wells,et al.  A structured interview version of the Hamilton Depression Rating Scale: evidence of reliability and versatility of administration. , 1990, Journal of psychiatric research.

[2]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[3]  W. Eaton,et al.  The epidemiology of blood-injection-injury phobia , 1998, Psychological Medicine.

[4]  S. Reingold,et al.  Revised estimate of the prevalence of multiple sclerosis in the united states , 1992, Annals of neurology.

[5]  R. Paul,et al.  Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI) , 1995, Neurology.

[6]  J. Breitner,et al.  Detection of dementia in the elderly using telephone screening of cognitive status , 1993 .

[7]  D. Mohr,et al.  Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment , 1996, Multiple sclerosis.

[8]  A. F. Fazio.  Implosive therapy in the treatment of a phobic disorder. , 1970 .

[9]  D. Rowland,et al.  Validation of a Telephone Cognitive Assessment Battery , 1997, Journal of The American Geriatrics Society.

[10]  A. Bandura.  Self-efficacy mechanism in human agency , 2024, Psihologìâ ì suspìlʹstvo.

[11]  D. A. Kenny,et al.  The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. , 1986, Journal of personality and social psychology.

[12]  J G Hamilton,et al.  Needle phobia: a neglected diagnosis. , 1995, The Journal of family practice.

[13]  C. G. Costello,et al.  Fears and phobias in women: a community study. , 1982, Journal of abnormal psychology.

[14]  C. Schwartz,et al.  Measuring self-efficacy in people with multiple sclerosis: a validation study. , 1996, Archives of physical medicine and rehabilitation.

[15]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[16]  T. Tatemichi,et al.  The Telephone Interview for Cognitive Status (TICS): Reliability and validity in a stroke sample , 1994 .

[17]  Cartwright Ps,et al.  Teenagers' perceptions of barriers to prenatal care. , 1993 .

[18]  B. Sharrack,et al.  The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis , 1999, Multiple sclerosis.

[19]  E. Ellinwood,et al.  Case report of a needle phobia. , 1991, The Journal of family practice.

[20]  C. Taylor,et al.  A rapid behavioral treatment for needle phobics. , 1978, The Journal of nervous and mental disease.

[21]  B. Tabachnick,et al.  Using Multivariate Statistics , 1983 .

[22]  D. Goodkin,et al.  Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la , 1998, Multiple sclerosis.

[23]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[24]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[25]  David A. Sylvester,et al.  The epidemiology of common fears and phobia. , 1969, Comprehensive psychiatry.

[26]  D. Goodin,et al.  Side effect profile of interferon beta-lb in MS , 1996, Neurology.

[27]  D. Goodkin.  The Natural History of Multiple Sclerosis , 1992 .

[28]  Evaluating the FONE FIM: Part II. Concurrent validity & influencing factors. , 1997, Journal of outcome measurement.

[29]  W. Heiss,et al.  New diagnostic criteria for multiple sclerosis , 2002, Annals of neurology.

[30]  E. Carmines,et al.  Analyzing models with unobserved variables: analysis of covariance structures , 1981 .

[31]  I. Rosenstock,et al.  The Role of Self-Efficacy in Achieving Health Behavior Change , 1986, Health education quarterly.

[32]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[33]  A Multiple Sclerosis (MS) Center Injection Training Program. , 1997 .